Forskning
Udskriv Udskriv
Switch language
Region Hovedstaden - en del af Københavns Universitetshospital
Udgivet

One-Year Follow-up on Liraglutide Treatment for Prediabetes and Overweight/Obesity in Clozapine- or Olanzapine-Treated Patients

Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

DOI

  1. Trajectory of cognitive functions in bipolar disorder: for better or worse?

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  2. Incidence of suicidal behaviour and violent crime following antidepressant medication: a Danish cohort study

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  3. Response to comment on Osler et al: misinterpretation of pre- and post differences invalidate the authors' conclusion

    Publikation: Bidrag til tidsskriftKommentar/debatForskningpeer review

  4. Societal costs of Borderline Personality Disorders: a matched-controlled nationwide study of patients and spouses

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  5. Meta-analysis of antidepressant effects of anti-inflammatory drugs-reply

    Publikation: Bidrag til tidsskriftKommentar/debatForskningpeer review

Vis graf over relationer

OBJECTIVE: Treatment with most antipsychotics is associated with an increased risk of weight gain and metabolic disturbances. In a randomized trial, we previously demonstrated that 16 weeks of glucagon-like peptide-1 receptor agonist liraglutide treatment vs. placebo significantly reduced glucometabolic disturbances and body weight in prediabetic, overweight/obese schizophrenia-spectrum disorder patients treated with clozapine or olanzapine. The aim of this study was to investigate whether the beneficial effects of the 16-week intervention were sustained beyond the intervention period.

METHOD: One year after completion of the intervention, we investigated changes in body weight, fasting glucose, glycated hemoglobin, C-peptide and lipids comparing one-year follow-up levels to end of treatment (week 16) and baseline (week 0) levels.

RESULTS: From end of treatment to the one-year follow-up, body weight had increased in the liraglutide-treated group. However, compared to baseline levels, the placebo-subtracted body weight loss remained significantly reduced (-3.8 kg, 95% CI: -7.3 to -0.2, P = 0.04). Fasting glucose, glycated hemoglobin, C-peptide and lipids had each returned to baseline levels one year after stopping liraglutide.

CONCLUSION: The body weight reduction during 16 weeks of liraglutide treatment was partially sustained one year after the intervention was completed. However, the improvements in other metabolic parameters returned to baseline levels. This article is protected by copyright. All rights reserved.

OriginalsprogEngelsk
TidsskriftActa Psychiatrica Scandinavica
Vol/bind139
Udgave nummer1
Sider (fra-til)26-36
Antal sider11
ISSN0001-690X
DOI
StatusUdgivet - jan. 2019

ID: 55633064